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Association of the type 1 protein phosphatase PP1 with the 
A-kinase anchoring protein AKAP220
Robynn V. Schillace and John D. Scott
The cyclic AMP (cAMP)-dependent protein kinase (PKA)
and the type 1 protein phosphatase (PP1) are broad-
specificity signaling enzymes with opposing actions
that catalyze changes in the phosphorylation state of
cellular proteins. Subcellular targeting to the vicinity of
preferred substrates is a means of restricting the
specificity of each enzyme [1,2]. Compartmentalization
of the PKA holoenzyme is mediated through
association of the regulatory subunits with A-kinase
anchoring proteins (AKAPs), whereas a diverse family
of phosphatase-targeting subunits directs the location
of the PP1 catalytic subunit (PP1c) [3,4]. Here, we
demonstrate that the PKA-anchoring protein, AKAP220,
binds PP1c with a dissociation constant (KD) of
12.1 ± 4 nM in vitro. Immunoprecipitation of PP1 from
cell extracts resulted in a 10.4 ± 3.8-fold enrichment of
PKA activity. AKAP220 co-purified with PP1c by affinity
chromatography on microcystin sepharose.
Immunocytochemical analysis demonstrated that the
kinase, the phosphatase and the anchoring protein had
distinct but overlapping staining patterns in rat
hippocampal neurons. Collectively, these results
provide the first evidence that AKAP220 is a multivalent
anchoring protein that maintains a signaling scaffold of
PP1 and the PKA holoenzyme.
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Results and discussion
AKAP220 was first identified in a screen for anchoring pro-
teins using radiolabelled regulatory subunit (RII) of PKA as
a probe and was shown to interact with the PKA holoen-
zyme inside cells [5]. Evidence that some AKAPs bind
other signaling enzymes [6–8] prompted us to look for
other AKAP220-interacting proteins. Residues 501–505 of
human AKAP220 contain the amino-acid sequence KVQF
(single-letter amino-acid code), which is a hallmark of type
I phosphatase targeting subunits (Figure 1a). Others have
noted that this loosely defined motif (R/K V/I X F) binds to
an allosteric site on the catalytic subunit of the phosphatase
[4,9]. We therefore screened a family of AKAP220 frag-
ments for their ability to bind the PP1cα isoform using an
overlay assay (Figure 1a,b). In this assay, immoblized pro-
teins are incubated with PP1 in solution and phosphatase
binding can be detected on the membrane by western blot-
ting analysis. Fragments encompassing the KVQF consen-
sus motif bound PP1cα, whereas a fragment lacking this
sequence did not bind the phosphatase (Figure 1c).
Further control experiments demonstrated that solid-phase
binding of PP1cα to AKAP220 was blocked by a peptide
spanning residues 492–514 of human AKAP220, but was
unaffected by preincubation with an RII-anchoring
inhibitor peptide derived from the human thyroid anchor-
ing protein Ht31 (Figure 1d,e). Formation of an
AKAP220–PP1cα complex in solution was observed in reci-
procal co-precipitation experiments. Recombinant PP1cα
was isolated upon immunoprecipitation of an AKAP220
fragment (Figure 1f). Similarly, the AKAP220–PP1cα
complex was isolated by immunoprecipitation with
isoform-specific anti-PP1α antibodies (Figure 1g). Neither
protein was immunoprecipitated by immunoglobulin G
(IgG) alone (Figure 1f,g). Collectively, these results
demonstrate that PP1cα and AKAP220 interact in vitro.
Recombinant PP1cα bound the phosphatase-binding-site
peptide of human AKAP220 with a dissociation constant
of 12.1 ± 4 nM (n = 3), as measured by surface plasmon
resonance (Figure 2a,b). Likewise, a peptide containing
the PP1-binding site of the muscle glycogen regulatory
subunit (GM) bound PP1cα with an affinity of 25 ± 5 nM
(n = 3). However, a peptide derived from the rat homo-
logue of AKAP220 bound the phosphatase with a 20-fold
lower binding affinity (322 ± 44 nM, n = 3). Alignment of
the human and rat sequences revealed a glycine for valine
substitution at position 502 in rat AKAP220 (Figure 2c).
Computer modeling of the human and rat PP1-binding
peptides using coordinates of the GM peptide bound to
PP1c highlights the importance of this residue [4]. The
valine side chain of human AKAP220 participates in the
formation of hydrophobic interactions with multiple
residues in the phosphatase catalytic subunit including
Ile169 (Figure 2d). Although rat AKAP220 lacks this side
chain, other critical residues in the PP1-binding site
remain and are sufficient to confer a nanomolar binding
affinity (Figure 2e). Furthermore, recent studies suggest
that sites other than the consensus binding motif con-
tribute to the high-affinity interaction between AKAP220
and the phosphatase [10–12].
In the light of the evidence that the rat AKAP220 homo-
logue bound to PP1 with a lower binding affinity than the
human homologue, it was imperative to determine
whether the proteins interacted inside cells. AKAP220 and
PP1 were isolated from rat brain extracts by affinity chro-
matography on microcystin–sepharose (Figure 3a). Control
experiments illustrated that isolation of both proteins was
322 Current Biology, Vol 9 No 6
Figure 1
(b) (c) (d) (e)(a)
338–422
180–1080
385–530
RII-binding
site
 KVQF
Full-length
AKAP220
97
200
116
18
0–
10
80
38
5–
53
0
33
8–
42
2
PT
G
18
0–
10
80
38
5–
53
0
33
8–
42
2
PT
G
18
0–
10
80
38
5–
53
0
33
8–
42
2
PT
G
18
0–
10
80
38
5–
53
0
33
8–
42
2
PT
G
55
45
35
29
An
ti-
AK
AP
22
0
An
ti-
PP
1α
Ig
G
200
kDa
116
97
68
45
31
21
Blot: Anti-AKAP220 
Blot: Anti-AKAP220 Blot: Anti-PP1α
PP1cα
overlay 
PP1cα overlay
+ peptide
PP1cα overlay
+ Ht31
An
ti-
AK
AP
22
0
An
ti-
PP
1α
Ig
G
(f) (g)
IP:
kDa
IP:
kDa
Current Biology
PP1α binds AKAP220 in vitro. (a) Schematic diagram of AKAP220
fragments used in overlay analysis: the amino-acid regions spanned by
each fragment and the location of consensus PP1-binding sites
(KVQF, blue boxes) and RII-binding sites (red boxes) are indicated.
The fragments shaded black (180–1080 and 385–530) bind PP1, the
unshaded fragment (338–422) does not bind PP1, and the full-length
AKAP220 protein has not been assayed for PP1 binding in vitro.
(b) Western blot detection of human AKAP220 fragments. Histidine-
tagged AKAP220 fragments were purified by FPLC, separated on
SDS–polyacrylamide (4–15%) gradient gels, and transferred to
Immobilon membrane; the phosphatase-targeting protein PTG [22]
was used as a control. Protein fragments were detected by western
blotting using a polyclonal antibody to human AKAP220. (c) Solid-
phase detection of PP1cα-binding proteins by overlay analysis.
Immobilon membranes containing AKAP220 protein fragments and
PTG were incubated with 0.5 µg recombinant PP1cα in TTBS (0.03%
Tween, Tris-buffered saline) for 2 h at room temperature. PP1cα was
detected by western blot analysis using a polyclonal anti-PP1cα
antibody and chemiluminescence (Pierce). (d) PP1 overlay in the
presence of 2 µM peptide corresponding to the PP1-binding site 
of AKAP220 (DVKESEHSGKKVQFAEALATHIL). (e) PP1cα overlay 
in the presence of 2 µM RII-anchoring inhibitor peptide Ht31
(DLIEEAASRIVDAVIEQVKAAGA) [23]. (f,g) Co-precipitation of PP1cα
and AKAP220. Recombinant PP1cα and AKAP220 fragment
containing amino acids 180–1080 were incubated for 30 min on ice in
50 mM Tris buffer pH 7.4, 0.1 mM EDTA, 1 mM DTT, 0.1% bovine
serum albumin, 1 mM MnCl2. Monoclonal antibodies to PP1cα or
AKAP220 (Transduction Labs), or mouse IgG (10 µg antibody in each
case) were added for 2 h at 4°C. Immune complexes were isolated by
incubation with protein A—Sepharose beads for 1 h at 4°C. After four
washes with TBS, 0.5 M NaCl, 0.5% Triton X-100, the beads were
boiled in sample buffer, separated by SDS–PAGE, and transferred to
Immobilon membrane for western blot analysis to detect (f) PP1cα and
(g) AKAP220. 
Figure 2
Human and rat AKAP220 interactions with PP1α. (a,b) Affinity
measurements of the PP1cα interaction with immobilized human
AKAP220 peptide by surface plasmon resonance, as described [24].
(a) Representative data of the real-time binding to a peptide
corresponding to amino acids 492–514 of human AKAP220 over a
range of PP1cα concentrations (2.8 nM–77 nM). (b) The graph of
extent of binding (units) plotted against concentration (nM) that was
used to determine the dissociation constant (KD). (c) Comparison of
PP1cα binding to the human AKAP220 peptide, the rat AKAP220
peptide, and the GM subunit peptide (± standard error). KD values
were calculated using nonlinear regression (Marquardt analysis) of a
single binding site equation with KaleidographTM, and are the average
from three independent experiments. (d,e) Computer-generated
modeling of (d) human AKAP220 peptide (green) and (e) rat
AKAP220 peptide (pink) using coordinates from the GM peptide–PP1
structure (white). Red, methyl group; blue, carboxyl group; yellow,
amine group.
PP1-binding motif    (K/R)(V/I) X F
Human AKAP220  DVKSEHSGKKVQFAEALATHIL   12.1 –  4 nM (n = 3)
Rat AKAP220    DVKSEHSGKKGQFADALATHIL  322  –  44 nM (n = 3)
GM subunit          SSGGRRVSFADNFGFN     25.5 –  5 nM (n = 3)
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prevented by preincubation with excess free microcystin
(Figure 3a). Complementary experiments demonstrated
that immunoprecipitation of the PP1β isoform resulted in
a 10.4 ± 3.8-fold (n = 3) enrichment of cAMP-dependent
kinase activity over the control (Figure 3b). As PKA activ-
ity was blocked by a peptide corresponding to amino acids
5–24 of the specific PKA inhibitor PKI, it is reasonable to
assume that the catalytic subunit of the kinase co-purified
with the phosphatase. Finally, confocal analysis of endoge-
nous AKAP220, PP1γ and RII in rat hippocampal neurons
indicated that the staining patterns for all three proteins
were distinct yet overlapping. PP1γ and RII were detected
in the cell body and the neurite extensions, whereas the
majority of AKAP220 staining was located in the cell body
(Figure 3c). Similar results were observed when the distri-
bution of AKAP220 was compared with PP1β (data not
shown). The evidence that a subset of all three proteins
occupy the same focal plane, when combined with in vitro
and cell-based data, lead to the proposal that AKAP220
interacts with a proportion of PP1 and PKA inside cells.
Targeting kinases and phosphatases close to their sites of
action allows for tight control of the phosphorylation state
of certain substrates. In some cases both enzymes directly
bind to each other [13–15], but often localization is medi-
ated by interactions with a targeting protein [16].
Although numerous PP1 regulatory subunits have been
identified [17–21], AKAP220 is the first example of a type
1 phosphatase targeting subunit that also binds to the PKA
holoenzyme. Our data suggest that a subpopulation of
each enzyme interacts with the anchoring protein. Our
data further illustrate that AKAP220 can interact with
multiple PP1 isoforms. While we have demonstrated that
PP1α interacts with AKAP220 in vitro, our cell-based
assays and immunoprecipitation data indicate that the
anchoring protein interacts with the PP1β and PP1γ iso-
forms inside cells. On the basis of these findings it would
appear that AKAP220 associates with multiple PP1 iso-
forms and conceivably could function to position PP1 and
PKA where they can reversibly modulate the phosphoryla-
tion state of as yet unidentified substrates.
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Rat AKAP220 interacts with PP1 and PKA inside cells. (a) PP1α and
AKAP220 can be isolated from rat cell extracts. Rat brain was
pulverized in liquid nitrogen and dounce-homogenized in Hendit buffer
(20 mM HEPES pH 7.4, 20 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.5%
Triton X-100, 1 mM AEBSF, 2 µg/ml leupeptin, and 1 mM
benzamidine), incubated on ice for 30 min and lysates were prepared
by centrifugation at 10,000 × g for 15 min at 4°C. Phosphatase
complexes were purified by affinity chromatography on
microcystin–sepharose [25]. Control extracts were preincubated with
excess free microcystin (0.5 µM) for 30 min on ice. Samples were
eluted in sample buffer, then separated by SDS–PAGE and
transferred to Immobilon membrane for western blot analysis with
monoclonal anti-rat AKAP220 antibodies (upper panel) or anti-PP1α
antibodies (lower panel). (b) Immunoprecipitation of PKA activity from
extract with PP1β antibodies. Rat testis extract was prepared as
described above. The extract (1 ml) was incubated with either rabbit
anti-PP1β antibody sera (anti-PP1) or pre-immune sera (control) for 2 h
at 4°C. Immune complexes were isolated by incubation with protein
A–Sepharose beads (30 µl) for 1 h at 4°C. After extensive washing
with 1 M NaCl Hendit buffer, the catalytic subunit was eluted with
1 mM cAMP and activity was assayed using Kemptide as substrate
[26]. PKA activity is defined as those counts (cpm) blocked by the
addition of the PKI 5–24 inhibitor peptide (PKI peptide) [27]. A
representative of three experiments is presented, with the error bars
showing the standard error within that one experiment. (c) AKAP220,
PP1γ and PKA occupy the same focal plane in neurons. Confocal
analysis of AKAP220 (green), PP1γ (red), and the RII subunit of PKA
(blue) in rat primary hippocampal neurons: a composite of the three
images is also shown. Neurons were fixed with 3.7% formaldehyde in
PBS for 5 min, washed twice with PBS, and permeabilized with ice-
cold acetone for 1 min. After washing twice with PBS/0.1% BSA,
primary antibodies (monoclonal anti-AKAP220 antibodies, rabbit
polyclonal anti-PP1γ1 antibodies, and goat polyclonal anti-RII
antibodies) were added for 1 h. Following three washes with
PBS/BSA, secondary antibodies (fluorescein-isothiocyanate-
conjugated donkey anti-mouse antibodies, Texas-Red-conjugated
donkey anti-rabbit antibodies, and Cy-5-conjugated donkey anti-goat
antibodies) were added for 1 h. The slides were washed with
PBS/BSA and mounted using Prolong mounting reagent (Molecular
Probes Inc). Confocal microscopy was performed on a MRC1024
Biorad UV/Vis system.
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